# D2C7-IT With Atezolizumab for Recurrent Gliomas

> **NCT04160494** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Darell Bigner** · enrollment: 18 (estimated)

## Conditions studied

- Malignant Glioma

## Interventions

- **DRUG:** D2C7-IT (6920 ng/mL via convection-enhanced delivery)
- **DRUG:** Atezolizumab (1200 mg every three weeks)
- **DRUG:** D2C7-IT (4613.2 ng/mL via convection-enhanced delivery)

## Key facts

- **NCT ID:** NCT04160494
- **Lead sponsor:** Darell Bigner
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-02-25
- **Primary completion:** 2024-06-28
- **Final completion:** 2027-12
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-05-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04160494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04160494, "D2C7-IT With Atezolizumab for Recurrent Gliomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04160494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*